Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline

Indian Journal of Medical Research

Volumn 134, Issue 9, 2011, Pages 314-319

  Walia, Rama ^a   Bhansali, Anil ^a   Dutta, Pinaki ^a   Khandelwal, Niranjan ^a   Sialy, Ravinder ^a   Bhadada, Sanjay ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Hypogonadism; Hypothalamus; Macroprolactinomas; Pituitary; Testis

Indexed keywords

CABERGOLINE; CABERLIN; CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; PROLACTIN; STEROID; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DRUG DOSE INCREASE; GONADOTROPIN RELEASE; HUMAN; HYPOPHYSIS; HYPOPHYSIS TESTIS SYSTEM; HYPOTHALAMO PITUITARY TESTICULAR AXIS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; NAUSEA; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SEMEN ANALYSIS; SOMNOLENCE; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; TESTIS FUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERGOLINES; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LUTEINIZING HORMONE; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RADIOIMMUNOASSAY; SPERM COUNT; SPERM MOTILITY; TESTIS; TESTOSTERONE; TIME FACTORS;

EID: 80054747230     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptin in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331: 904-9.
2. Verhest J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84: 2518-22.
3. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 2003: 58: 662-70.
4. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138: 286-93.
5. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24 months treatment on prolactin levels, tumor mass, recovery of pituitary function and semen analysis. J Clin Endocrinol Metab 2004; 89: 1704-11.
6. Horseman ND, Gregerson KA: Prolactin. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia: Elsevier Saunders; 2006. p. 309-21.
7. Hondo E, Kurohmaru M, Sakai S, Ogawa K, Hayashi Y. Prolactin receptor expression in rat spermatogenic cells. Biol Reprod 1995; 52: 1284-90
8. Bex FJ, Bartke A. Testicular LH binding in the hamster: modification by photo period and prolactin. Endocrinology 1977; 100: 1223-6.
9. Bere F, Bartke A, Goldman BD and Dalterio S. Prolactin, growth hormone, luteinizing hormone receptors and seasonal changes in testicular activity in the golden hamster. Endocrinology 1978; 103: 2069-80.
10. Carter JN, Tyson JE, Tolis G, Van Vliet S. Faiman C, Friesen HG. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978; 299: 847-52.
11. Segal S. Yaffe H, Laufer N, Ben-David M. Male hyperprolactinemia: effects on fertility. Fertil Steril 1979; 32: 556-61.
12. Matsuzaki T, Azyuma K, Irahara M, Yasuit T, Aono T. Mechanism of anovulation in hyperprolactinemic amenorrhea determined by pulsalite gonadotropin-releasing hormone injection combined with human chorionic gonadotropin. Fertil Steril 1994; 62: 1143-9.
13. Moult PJ, Rees LH, Besser GM. Pulsalite gonadotrophin secretion in hyperprolactinaemic amenorrhoea and the response to bromocriptine therapy. Clin Endocrinol (Oxf) 1982; 16: 153-62.
14. Koizumi K, Aono T, Koike K, Kurachi K. Restoration of LH pulsatility in patients with prolactinomas after transphenoidal surgery. Acta Endocrinol (Copenh) 1984; 107: 433-8.
15. Bhasin S, Jameson JL. Disorders of the testes and male reproductive system. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrisons'principles of internal medicine. New York: The McGraw Hill Companies, Inc., 2005. p. 2185-97.
16. Kauschansky A, Dickerman Z, Phillip M, Weintrob N, Strich D. Use of GnRH agonist and human chorionic gonadotrophin tests for differentiating constitutional delayed puberty from gonadotrophion deficiency in boys. Clin Endocrinol 2002; 56: 603-7.
17. World Health Organization. WHO Laboratory manual for the examination of human semen and sperm-cervical mucus interactions. Cambridge, UK: Cambridge University Press; 1992.
18. Lundin P, Pedersen F. Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 1992; 16: 518-28.
19. Inder WJ, Hunt PJ. Glucocorticoid replacement in pituitary surgery: Guidelines for perioperative assessment and management. J Clin Endocrinol Metab 2002: 87: 2745-50.
20. Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. Indian J Med Res 2010; 131: 530-5.
21. Chaplin MD. Bioavailability of nafarelin in healthy volunteers. Am J Obstet Gynecol 1992; 166: 726-5.
22. Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactin-secreting macroadenomas with the once weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-43.